nach oben

Drugs

Erschienen in:

01.11.2004 | Review Article

Progesterone Treatment to Prevent Preterm Birth

verfasst von: Dr Paul J. Meis, Alicia Aleman

Erschienen in: Drugs | Ausgabe 21/2004

Einloggen, um Zugang zu erhalten

Abstract

The publication in 2003 of two large randomised trials of progesterone therapy to prevent preterm delivery has generated renewed interest in this treatment and has added substantial numbers of subjects to previously published small trials. The randomised trials of progestogens have generally shown efficacy in reducing the rate of recurrent preterm delivery in women with singleton pregnancies who were at high risk for preterm labour and delivery. Most of the successful trials have employed 17α-hydroxyprogesterone caproate, and one trial has reported positive results using progesterone vaginal suppositories.

The administration of 17α-hydroxyprogesterone caproate or progesterone suppositories to women with these high-risk pregnancies showed a significant protective effect for preterm birth in six of the seven published trials. No successful trials of progestogens have been reported for women at risk for preterm delivery because of multiple gestations. Trials of progestogens after the occurrence of symptoms of labour have shown them to be ineffective in prolonging pregnancy.

The use of trade names is for product identification purposes only and does not imply endorsement.

da Fonseca EB, Bittar RE, Carvalho MHB, et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419–24PubMedCrossRef

Meis PJ, Klebanoff M, Thom E, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379–85PubMedCrossRef

Paneth NS. The problem of low birth weight. Future Child 1995; 5: 19–34PubMedCrossRef

Mattison DR, Damus K, Fiore E, et al. Preterm delivery: a public health perspective. Paediatr Perinat Epidemiol 2001; 15 Suppl. 2: 7–16PubMedCrossRef

Gyetvai D, Hannah ME, Hodnett ED, et al. Tocolytics for preterm labor: a systematic review. Obstet Gynecol 1999; 94: 869–77PubMedCrossRef

Harger JH. Cerclage and cervical insufficiency: and evidencebased analysis. Obstet Gynecol 2002; 100: 1313–27PubMedCrossRef

Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic vacterial vaginosis. N Engl J Med 2000; 342: 534–40PubMedCrossRef

Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asyptomatic Trichomonas Vaginalis infection. N Engl J Med 2001; 345: 487–93PubMedCrossRef

Creasy RK. Preterm birth prevention: where are we? Am J Obstet Gynecol 1993; 168: 1223–30PubMed

10.

Rebar RW, Cedars MI. Hypergonadotropic forms of amenorrhea in young women. Endocrinol Metab Clin North Am 1992 Mar; 21(1): 173–91PubMed

11.

Stites SP, Siiteri PK. Steroids as immunosppressants in pregnancy. Immunol Rev 1983; 75: 117–38PubMedCrossRef

12.

Siiteri PK, Seron-Ferre M. Some new thoughts on the fetoplacental unit and parturition in primates. In: Novy JM, Reskko AJ, editors. Fetal endocrinology. New York: Academic Press, 1981: 1–34

13.

Garfield RE, Dannan MS, Daniel EE. Gap junction formation in myometrium: control by estrogens, progesterone, and prostaglandins. Am J Physiol 1980; 238: C81–9PubMed

14.

Challis JR. Sharp increase in free circulating oestrogens immediately before parturition in sheep. Nature 1971; 229: 208PubMedCrossRef

15.

Csapo AI. Progesterone ‘block’. Am J Anat 1956; 98: 273–91PubMedCrossRef

16.

Cousins LM, Hobel CJ, Chang RJ, et al. Serum progesterone and estradiol-17β levels in premature and term labor. Am J Obstet Gynecol 1977; 127: 612–5PubMed

17.

Johnson JWC, Lee PA, Zachary AS, et al. High-risk prematurity-progestin treatment and steroid studies. Obstet Gynecol 1979; 54: 412–8PubMedCrossRef

18.

Mitchell B, Cruickshank B, McLain D, et al. Local modulation of progesterone production in human fetal membranes. J Clin Endocrinol Metab 1982; 55: 1237–9PubMedCrossRef

19.

Romero R, Scoccia B, Mazor M, et al. Evidence for a local change in the progesterone/estrogen ratio in human parurition at term. Am J Obstet Gynecol 1988; 159: 657–60PubMed

20.

Mazor M, Wiznitzer A, Levy J, et al. The relationship between estrogen/progesterone ratio and term human parturition. Isr J Med Sci 1993; 29: 97–9PubMed

21.

Darne J, McGarrigle HHG, Lachelin GCL. Saliva oestriol, oestradiol, oestrone and progesterone levels in pregnancy: spontaneous labor at term is preceded by a prise in the saliva oestriol: progesterone ratio. Br J Obstet Gynaecol 1987; 94: 227–35PubMedCrossRef

22.

Jackson GM, McGregor JA, Lachelin GCL, et al. Salivary estriol rise predicts preterm labor. Am J Obstet Gynecol 1995; 172: 406CrossRef

23.

Buster JE, Meis PJ, Hobel CJ, et al. Subhourly variability of circulating third trimester maternal steroid concentrations as a source of sampling error. J Clin Endocrinol Metab 1978; 46: 907–10PubMedCrossRef

24.

Frydman R, LeLaidier C, Baton C, et al. Labor induction in women at term with mifepristone (RU 486): a double-blind, randomized, placebo-controlled study. Obstet Gynecol 1992; 80: 972–5PubMed

25.

LeLaidier C, Baton C, Beniifla JL, et al. Mefipristone for labour induction after previous caesarean section. Br J Obstet Gynecol 1994; 101: 501–3CrossRef

26.

Chwalisz K, Fahrenholz F, Hackenbery M, et al. The progesterone antagonist onapristone increases the effectiveness of oxytocin to produce delivery without changing the myometrial oxutocin receptor concentrations. Am J Obstet Gynecol 1991; 165: 1760–70PubMed

27.

Swyer GIM, Daley D. Progesterone implantation in habitual abortion. BMJ 1953 May 16; 1(4819): 1073–7PubMedCrossRef

28.

Goldzieher J. Double-blind trial of a progestin in habitual abortion. JAMA 1964; 188: 651–4PubMedCrossRef

29.

Hobel CJ, Ross MG, Bemis RL, et al. The West Los Angeles Preterm Birth Prevention Project. I: program impact on highrisk women. Am J Obstet Gynecol 1994; 170: 54–62

30.

LeVine L. Habitual abortion: a controlled clinical study of pregestational therapy. World J Surg 1964; 72: 3036

31.

Papiernik E. Double blind study of an agent to prevent pre-term delivery among women at increased risk [in French]. Edition Schering 1970; Serie IV, fiche 3: 65–8

32.

Johnson JWC, Austin KL, Jones GS, et al. Efficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975; 292: 675–80CrossRef

33.

Yemini M, Borenstein R, Dreazen E, et al. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol 1985; 151: 574–7PubMed

34.

Suvonnakote T. Prevention of pre-term labour with progesterone. J Med Assoc Thailand 1986; 69: 538–42

35.

Hartikainen-Sorri AL, Kauppila A, Tuimala R. Inefficacy of 17 alpha hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy. Obstet Gynecol 1980; 56: 692–5PubMed

36.

Hauth JC, Gilstrap LC, Brekken AL, et al. The effect of 17 alpha-hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983; 146: 187–19PubMed

37.

Goldstein P, Berrier J, Rosen S, et al. A meta-analysis of randomized control trials of progestational agents in pregnancy. Br J Obstet Gynecol 1989; 96: 265–74CrossRef

38.

Keirse MJNC. Progesterone administration in pregnancy may prevent pre-term delivery. Br J Obstet Gynecol 1990; 97: 149–54CrossRef

39.

Fuchs F, Stademann G. Treatment of threatened premature labor with large doses of progesterone. Am J Obstet Gynecol 1960; 79: 172–6PubMed

40.

Kaupilla A, Hartikainen-Sorri A-L, Olli J, et al. Suppression of threatened premature labor by administration of cortisol and 17 alpha-hydroxyprogesterone caporate: a comparison with ritodrine. Am J Obstet Gynecol 1980; 138: 404–8

41.

Erny R, Pigne C, Prouvost M, et al. The effects of oral administration of progesterone for premature labor. Am J Obstet Gynecol 1986; 154: 525–9PubMed

42.

Noblot G, Audra P, Dargent D, et al. The use of micronized progesterone in the treatment of menace of preterm delivery. Eur J Obstet Gynecol Reprod Biol 1991; 40: 203–9PubMedCrossRef

43.

Brenner WE, Hendricks CH. Effect of medroxyprogesterone acetate upon the duration and characteristics of human gestation and labor. Am J Obstet Gynecol 1962; 83: 1094–8PubMed

Titel: Progesterone Treatment to Prevent Preterm Birth
verfasst von: Dr Paul J. Meis
Alicia Aleman
Publikationsdatum: 01.11.2004
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 21/2004
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200464210-00007

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Progesterone Treatment to Prevent Preterm Birth

Abstract

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 21/2004

Trospium Chloride in the Management of Overactive Bladder

Therapeutic Potential of Oral Antiproliferative Agents in the Prevention of Coronary Restenosis

Long-Cycle Treatment with Oral Contraceptives

Gefitinib

Management of Acute and Chronic Gouty Arthritis

Topical Antibacterial Therapy for Acne Vulgaris